IL161092A0 - N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds - Google Patents

N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds

Info

Publication number
IL161092A0
IL161092A0 IL16109202A IL16109202A IL161092A0 IL 161092 A0 IL161092 A0 IL 161092A0 IL 16109202 A IL16109202 A IL 16109202A IL 16109202 A IL16109202 A IL 16109202A IL 161092 A0 IL161092 A0 IL 161092A0
Authority
IL
Israel
Prior art keywords
phenylamines
methylthiazol
pyrimidin
antiproliferative compounds
antiproliferative
Prior art date
Application number
IL16109202A
Other languages
English (en)
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0123377A external-priority patent/GB0123377D0/en
Priority claimed from GB0123629A external-priority patent/GB0123629D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of IL161092A0 publication Critical patent/IL161092A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Refuge Islands, Traffic Blockers, Or Guard Fence (AREA)
IL16109202A 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds IL161092A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123377A GB0123377D0 (en) 2001-09-28 2001-09-28 Anticancer compounds
GB0123629A GB0123629D0 (en) 2001-10-02 2001-10-02 Anticancer compounds
PCT/GB2002/004383 WO2003029248A1 (en) 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds

Publications (1)

Publication Number Publication Date
IL161092A0 true IL161092A0 (en) 2004-08-31

Family

ID=26246590

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16109202A IL161092A0 (en) 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds

Country Status (13)

Country Link
US (2) US7388015B2 (xx)
EP (2) EP1430051B1 (xx)
JP (1) JP4495963B2 (xx)
CN (1) CN100500663C (xx)
AT (1) ATE349443T1 (xx)
BR (1) BR0212944A (xx)
CA (1) CA2460909A1 (xx)
CZ (1) CZ2004354A3 (xx)
DE (1) DE60217140T2 (xx)
IL (1) IL161092A0 (xx)
MX (1) MXPA04002914A (xx)
NZ (1) NZ531596A (xx)
WO (1) WO2003029248A1 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
AU2004285745A1 (en) 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
WO2005040135A1 (ja) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CA2576159A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
BRPI0517253A (pt) * 2004-10-28 2008-10-07 Irm Llc compostos e composições como moduladores de trajetória de ouriço
CA2590939C (en) * 2004-12-17 2011-10-18 Amgen Inc. Aminopyrimidine compounds and methods of use
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CA2636077C (en) * 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CN101928258B (zh) * 2010-08-18 2014-10-29 杭州民生药业有限公司 1-(2-取代苯胺基-4-甲基-噻唑-5)-3-取代苯基-丙烯酮衍生物、制备方法及其制药用途
CN103058949A (zh) * 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
CN105267214B (zh) * 2014-07-21 2019-04-30 沈阳化工研究院有限公司 N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途

Also Published As

Publication number Publication date
US20060199830A1 (en) 2006-09-07
CN1617870A (zh) 2005-05-18
US7388015B2 (en) 2008-06-17
EP1760082A1 (en) 2007-03-07
CA2460909A1 (en) 2003-04-10
MXPA04002914A (es) 2005-06-20
JP2005508931A (ja) 2005-04-07
JP4495963B2 (ja) 2010-07-07
CN100500663C (zh) 2009-06-17
NZ531596A (en) 2005-08-26
EP1430051A1 (en) 2004-06-23
US20040259894A1 (en) 2004-12-23
WO2003029248A1 (en) 2003-04-10
US7427627B2 (en) 2008-09-23
EP1430051B1 (en) 2006-12-27
CZ2004354A3 (cs) 2004-06-16
DE60217140D1 (de) 2007-02-08
ATE349443T1 (de) 2007-01-15
BR0212944A (pt) 2004-10-13
DE60217140T2 (de) 2007-04-19

Similar Documents

Publication Publication Date Title
IL161092A0 (en) N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
GB0226583D0 (en) Compounds
GB2375534B (en) Anti-cancer compounds
HK1062440A1 (en) Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
AU3113902A (en) Thiazolyl inhibitors of tec family tyrosine kinases
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
NL300357I2 (nl) Beta-amino tetrahydroimidazo (1,2-A)pyrazines en
NO20074964L (no) Pyrimidinderivater for behandling av hyperproliferative forstyrrelser
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
MY143466A (en) Inhibitors of tyrosine kinases
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
IL179883A0 (en) 4,6-disubstituted pyrimidine derivatives and pharmaceutical compositions containing the same
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
WO2003028721A3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
ATE309223T1 (de) Cyclin-abhängige kinase inhibitoren
EA200501233A1 (ru) 4-аминопиримидин-5-он
PL375697A1 (en) Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
MXPA05010975A (es) Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2002059109A3 (en) Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases
BRPI0416777A (pt) composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase